Proactiveinvestors recommends
Additional Information
Market: AIM
Sector: Chemicals
EPIC: PIM
Latest Price: 16.50  (8.20% Ascending)
52-week High: 32.50
52-week Low: 15.25
Market Cap: 8.31M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Plant Impact
www.plantimpact.com

 

Plant Impact's range of crop nutrition products focus on crop enhancement. They improve crop performance and crop health giving growers increased marketable yields, better quality and longer shelf life with reduced environmental impact.

 

Full Plant Impact profile here
Pdf

Allenby Capital sees potential in Plant Impact

16th Mar 2010, 3:39 pm

Allenby Capital said that Plant impact (AIM: PIM), the developer of technologies that improve crop productivity, has world-class products and its sales are growing. According to the broker, increasing pressure on arable land, coupled with a consumer driven shift away from synthetic chemical agricultural products is creating a mass market, worth US$105bn, for ecologically sound alternatives.

“With sales revenues poised to accelerate on the back of a licensing deal with Arysta Life Sciences and a £2m equity raise, we see Pi as undervalued against forecast future cash flow and against its closest peer” it stated.

According to Allenby, Plant Impact is at a similar stage to its peer Plant Health Care (AIM: PHC), which it currently values at £110m. The stockbroker estimates Plant Impact’s enterprise value (EV) at £26m based on future cash flows from sales of CaT, PiNT and BugOil technologies alone.

At 18.5p per share, Plant Impact’s market capitalisation is currently £8.4m.

The broker did not include the Speedo product in the valuation nor did it consider the products in its development pipeline, including Nematicide which is considered to have the greatest market potential of all Plant Impacts products, Allenby noted.

The research note also stated that the company’s lead pesticide BugOil will achieve further sales through its licensing deal with agrochemical major Arysta Life Sciences, once it receives regulatory approval which is expected in 2010. Allenby also expects an accelerated sales performance following February’s £2m fund-raising which is funding expended sales and marketing operations.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.